Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

Science Translational Medicine(2022)10.1126/scitranslmed.abj3776Source: DataRank Database

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria is a research paper published in Science Translational Medicine (2022). On theSindex it has a DataRank of 0.598. It has been cited 53 times.

N/A

0.598DataRank · unranked

Scored on demand from live citation data

Open Access53 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Topics (11)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.598

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (28)

Alphonse Ouédraogo ORCID,Alfred B. Tiono ORCID,Jean Moïse Tanga Kaboré ORCID,Edith C. Bougouma ORCID,Maurice Ouattara ORCID

Live enrichment

PubMed:36475905 PMC:PMC10041996

NIAID NIH HHS

Grant: R44 AI055229

NIAID NIH HHS

Grant: U01 AI112367

National Institutes of Health

Grant: 1U01AI112367-01

Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adults

National Institutes of Health

Grant: 5R44AI055229-10

Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

AnimalsHumansSporozoitesVaccines

Keywords

VaccinesSporozoitesHumansAnimals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice

Additional file 6 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709074.v1figshare

Additional file 6 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709074figshare

Additional file 5 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709071.v1figshare

Additional file 5 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709071figshare

Additional file 4 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709068.v1figshare

Additional file 4 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709068figshare

Additional file 3 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709065figshare

Additional file 3 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.26709065.v1figshare

Additional file 2 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.25656142.v1figshare

Additional file 2 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.25656142figshare

Additional file 1 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.25656021.v1figshare

Additional file 1 of Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro

10.6084/m9.figshare.25656021figshare

Additional file 1 of Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

10.6084/m9.figshare.24873028.v1figshare

Additional file 1 of Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

10.6084/m9.figshare.24873028figshare

Related Papers (10)

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

N/A

2.6DataRank · unranked

The Lancet Infectious Diseases(2022)

co-cited

10.1016/s1473-3099(22)00273-0

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

N/A

1.2DataRank · unranked

The Lancet Infectious Diseases(2023)

co-cited

10.1016/s1473-3099(22)00793-9

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial

N/A

1.7DataRank · unranked

The Lancet Infectious Diseases(2021)

co-cited

10.1016/s1473-3099(21)00332-7

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial

N/A

1.5DataRank · unranked

The Lancet Infectious Diseases(2023)

co-cited

10.1016/s1473-3099(23)00276-1

A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection

N/A

0.590DataRank · unranked

Science Translational Medicine(2022)

co-citedsame journal

10.1126/scitranslmed.abn9709

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

N/A

2.2DataRank · unranked

Journal of Clinical Investigation(2021)

co-cited

10.1172/jci146221

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

N/A

2.9DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-021-01470-y

Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial

N/A

1.3DataRank · unranked

Nature Communications(2021)

co-cited

10.1038/s41467-021-22740-w

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

N/A

3.9DataRank · unranked

New England Journal of Medicine(2022)

co-cited

10.1056/nejmoa2206966

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

N/A

3.6DataRank · unranked

New England Journal of Medicine(2022)

co-cited

10.1056/nejmoa2203067

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

FAIR Checklist

DataRank Breakdown

Authors (28)

Funding (4 grants)

Topics

Linked Datasets (14)

Annotations (Europe PMC)

Related Papers (10)